NSABP B-42 Trial shows MammaPrint Low Risk is Predictive of EET – JCO Publication
Journal of Clinical Oncology, July 24, 2024 Authors: Rastogi, et al.
Read MoreGene-expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research, Vol 30, Issue 14, July 15 2024 Author: Bottosso et al.
Read MoreB-42 Trial: MammaPrint Utility for Prediction of Extended Letrozole Therapy, ASCO 2021
NSABP B-42 Trial, ASCO 2021 Abstract #502 Authors: Rastogi, et al.
Read More
